SEC Form 4 · accession 0001193125-26-394342
Avalyn Pharma Inc. · AVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert J. Meyer
Director
Period of report
Sep 15, 2026
Accepted (ET)
Sep 17, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001540171
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $34.28 | Sep 15, 2026 | A | 31,182 | A | — | Sep 14, 2036 | Common Stock | 31,182 | 31,182 | D |
Explanation of responses
- F1The shares underlying this option vest and become exercisable in three equal annual installments following the grant date, subject to the Reporting Person's continued service on each such vesting date.